Key clinical point : No significant difference was seen in the 1-year relapse-free survival (RFS) relapse-free survival rate (RFS) and overall survival (OS) between intermediate-dose cytarabine (IDAC) and high-dose cytarabine (HiDAC) in patients with acute myeloid leukemia (AML).
Major finding : One-year RFS was 63.33% in the IDAC group vs. 46.87% in the HiDAC group ( P = .137). One-year OS was 93.33% in the IDAC group vs. 84.37% in the HiDAC group ( P = .691). IDAC group vs HiDAC group had significantly shorter duration of grade 3–4 thrombocytopenia (mean duration, 14.69 vs. 23.84 days; P = .045).
Study details : The data come from a retrospective study involvoing 62 patients with AML (30 patients in IDAC and 32 patients in HiDAC regimen).
Disclosures: The authors declared no conflicts of interest.
Source: Tangchitpianvit K et al. Hematology. 2021 Apr 14. doi: 10.1080/16078454.2021.1912949 .